Journal
DIABETES & VASCULAR DISEASE RESEARCH
Volume 16, Issue 2, Pages 128-132Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1479164119827570
Keywords
Insulin resistance; diabetes therapies; metformin; sulfonylureas; glucagon-like peptide-1 receptor agonists; insulin; thiazolidinediones; dipeptidyl peptidase-4 inhibitors
Ask authors/readers for more resources
Insulin resistance has a broad pathogenic impact affecting metabolic, cardio-renal and other disease areas. Extensive studies to dissect the mechanisms of insulin resistance have provided valuable insights to shape current clinical awareness and advance therapeutic practice. However, the development of direct interventions against insulin resistance has been hindered by its complex and highly variable presentations, especially in type 2 diabetes. Among glucose-lowering agents, metformin and thiazolidinediones provide cellular actions that counter some effects of insulin resistance: reduced glucotoxicity and weight-lowering with antidiabetic therapies also improve insulin action, except that endogenously- or exogenously-created hyperinsulinaemia may partially compromise these benefits. Increasing awareness of the pervasiveness and damaging ramifications of insulin resistance heightens the need for more specifically targeted and more effective therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available